Blueshift Asset Management LLC Acquires Shares of 1,697 United Therapeutics Corporation (NASDAQ:UTHR)

Key Points

• Blueshift Asset Management LLC has acquired 1,697 shares of United Therapeutics Corporation for approximately $523,000 during the first quarter, reflecting continued institutional interest in the company.
• United Therapeutics reported $6.41 earnings per share for the last quarter, falling short of analysts' estimates, though revenue increased by 11.7% compared to the previous year.
• Analysts have varying ratings for United Therapeutics, with a mix of upgrades and downgrades leading to an average price target of $379.69 and a "Moderate Buy" rating.

Blueshift Asset Management LLC purchased a new stake in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) in the first quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 1,697 shares of the biotechnology company's stock, valued at approximately $523,000.

Other large investors have also recently modified their holdings of the company. Dunhill Financial LLC increased its holdings in shares of United Therapeutics by 100.0% in the 4th quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company's stock worth $35,000 after buying an additional 50 shares during the last quarter. Sound Income Strategies LLC bought a new position in United Therapeutics in the first quarter worth about $49,000. State of Wyoming acquired a new stake in United Therapeutics in the fourth quarter valued at approximately $62,000. Curat Global LLC purchased a new position in United Therapeutics during the 1st quarter worth $63,000. Finally, Natixis purchased a new position in shares of United Therapeutics in the 4th quarter valued at approximately $85,000. Hedge funds and other institutional investors own 94.08% of the company's stock.

United Therapeutics Stock Performance

Shares of NASDAQ UTHR traded down $1.63 during midday trading on Monday, hitting $292.65. 909,297 shares of the stock traded hands, compared to its average volume of 547,628. The business has a 50 day moving average price of $298.13 and a two-hundred day moving average price of $312.88. United Therapeutics Corporation has a one year low of $266.98 and a one year high of $417.82. The company has a market cap of $13.20 billion, a PE ratio of 11.42, a P/E/G ratio of 4.43 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). The firm had revenue of $798.60 million for the quarter, compared to analysts' expectations of $802.13 million. United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The business's quarterly revenue was up 11.7% on a year-over-year basis. During the same period in the prior year, the business posted $5.85 earnings per share. As a group, equities research analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on UTHR shares. JPMorgan Chase & Co. lowered their target price on shares of United Therapeutics from $350.00 to $330.00 and set an "overweight" rating on the stock in a research note on Tuesday, July 8th. HC Wainwright lowered their price objective on United Therapeutics from $425.00 to $400.00 and set a "buy" rating for the company in a research report on Thursday. Cantor Fitzgerald started coverage on United Therapeutics in a report on Monday, June 2nd. They issued an "overweight" rating and a $405.00 price objective for the company. Wells Fargo & Company reduced their price target on United Therapeutics from $314.00 to $295.00 and set an "equal weight" rating for the company in a report on Thursday. Finally, UBS Group lowered their target price on United Therapeutics from $410.00 to $385.00 and set a "buy" rating on the stock in a report on Monday, June 30th. Four analysts have rated the stock with a hold rating and ten have given a buy rating to the company's stock. According to data from MarketBeat, United Therapeutics has an average rating of "Moderate Buy" and an average target price of $379.69.

Insider Activity at United Therapeutics

In other United Therapeutics news, EVP Paul A. Mahon sold 11,000 shares of the firm's stock in a transaction dated Thursday, July 24th. The stock was sold at an average price of $304.11, for a total value of $3,345,210.00. Following the completion of the sale, the executive vice president owned 36,781 shares of the company's stock, valued at approximately $11,185,469.91. This trade represents a 23.02% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Richard Giltner sold 3,036 shares of the business's stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $289.60, for a total transaction of $879,225.60. Following the transaction, the director owned 19,384 shares of the company's stock, valued at $5,613,606.40. This represents a 13.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 70,681 shares of company stock valued at $21,318,359. Corporate insiders own 10.30% of the company's stock.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.